Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Alzamend Neuro, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −1 vs. Q1 2026
- Shares held
- 2.72M
- +2.04M (+298.6%) vs. Q1 2026
- Total value
- $3.26M
- +$2.54M (+351.3%) vs. Q1 2026
- New holders
- 2
- 2 more added
- Sold out
- 3
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $3.26M |
| Q1 2026 | 13 | $723.1K |
| Q4 2025 | 13 | $447.2K |
| Q3 2025 | 11 | $351.3K |
| Q2 2025 | 7 | $6.36K |
| Q1 2025 | 11 | $59.9K |
| Q4 2024 | 17 | $131.7K |
| Q3 2024 | 12 | $71.2K |
| Q2 2024 | 16 | $150.5K |
| Q1 2024 | 13 | $386.8K |
| Q4 2023 | 16 | $334.7K |
| Q3 2023 | 27 | $1.49M |
| Q2 2023 | 24 | $3.13M |
| Q1 2023 | 26 | $2.64M |
| Q4 2022 | 33 | $3.98M |
| Q3 2022 | 17 | $9.41M |
| Q2 2022 | 21 | $2.70M |
| Q1 2022 | 22 | $4.01M |
| Q4 2021 | 20 | $1.66M |
| Q3 2021 | 17 | $1.99M |
| Q2 2021 | 11 | $2.58M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Alzamend Neuro, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 1,329,100 | $1.59M | 1.35% | +762,367+134.5% | Added |
| KMT Wealth Management, LLC | 1,329,100 | $1.59M | 1.35% | +1,329,100 | New |
| Geode Capital Management, LLC | 26,371 | $31.6K | 0.00% | −19,309−42.3% | Reduced |
| Vanguard Fiduciary Trust Co | 21,020 | $25.2K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,556 | $9.07K | 0.00% | +3,156+71.7% | Added |
| Tower Research Capital LLC (TRC) | 3,517 | $4.22K | 0.00% | −2,667−43.1% | Reduced |
| UBS Group AG | 2,352 | $2.82K | 0.00% | −2,152−47.8% | Reduced |
| BlackRock, Inc. | 437 | $524 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 22 | $26 | 0.00% | 00.0% | Unchanged |
| IFG Advisory, LLC | 22 | $26 | 0.00% | +22 | New |
| Caitong International Asset Management Co., Ltd | 3 | $4 | 0.00% | −1−25.0% | Reduced |
| Harbor Investment Advisory, LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −5,231−100.0% | Sold out |